SRSF2 and myelodysplastic syndrome: Several prominent targets include chromatin modifiers EZH2 (inclusion of a “poison” exon that induces NMD and global transcript downregulation), BCOR (cassette exon splicing), CASP8 (cassette exon splicing that results in generation of a novel truncated isoform73), and FYN (mutually exclusive exons).72, 74 Interestingly, EZH2 loss‐of‐function mutations and SRSF2 missense mutations are highly mutually exclusive in MDS patients, and the ability of mutant SRSF2 to suppress EZH2 may represent a mechanistic explanation for this observation.53, 68